Company intelligence / Profile preview

Sophos

Ownership: Public · SOPH
Development stage: Commercial

Overview

Sophos Biotech specialized in providing high-quality generic and specialty pharmaceuticals for the treatment of cancer, mucositis, prostate conditions, and pain. The company emphasized effectiveness, safety, economic impact for healthcare systems, and improving patient quality of life. It was acquired by Societa Prodotti Antibiotici in November 2023.

Therapeutic areas: OncologyGastroenterologyNeurologyMen's Health
Modalities: Small moleculeGeneric drugs
Industry: Biotech

Financials

Market cap: $209.8M
Total revenue: $17.8M
Enterprise value: $171.5M

Beyond the preview

Go deeper on Sophos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sophos.

Explore the full profile